As of 2026-09-27, the EV/EBITDA ratio of Heron Therapeutics Inc (HRTX) is -13.75. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. HRTX's latest enterprise value is 177.62 mil USD. HRTX's TTM EBITDA according to its financial statements is -12.92 mil USD. Dividing these 2 quantities gives us the above HRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.3x - 15.7x | 13.2x |
| Forward P/E multiples | 10.4x - 17.5x | 14.6x |
| Fair Price | (1.36) - (1.72) | (1.59) |
| Upside | -561.2% - -683.7% | -640.3% |
| Date | EV/EBITDA |
| 2026-09-25 | -13.75 |
| 2026-09-24 | -13.69 |
| 2026-09-23 | -13.70 |
| 2026-09-22 | -13.82 |
| 2026-09-21 | -13.39 |
| 2026-09-18 | -13.97 |
| 2026-09-17 | -14.06 |
| 2026-09-16 | -14.09 |
| 2026-09-15 | -14.04 |
| 2026-09-14 | -14.06 |
| 2026-09-11 | -14.06 |
| 2026-09-10 | -14.16 |
| 2026-09-09 | -14.32 |
| 2026-09-08 | -14.56 |
| 2026-09-04 | -14.48 |
| 2026-09-03 | -14.27 |
| 2026-09-02 | -14.02 |
| 2026-09-01 | -14.05 |
| 2026-08-31 | -14.10 |
| 2026-08-28 | -14.22 |
| 2026-08-27 | -14.30 |
| 2026-08-26 | -14.01 |
| 2026-08-25 | -14.17 |
| 2026-08-24 | -14.17 |
| 2026-08-21 | -14.10 |
| 2026-08-20 | -13.96 |
| 2026-08-19 | -14.05 |
| 2026-08-18 | -13.85 |
| 2026-08-17 | -14.13 |
| 2026-08-14 | -14.37 |
| 2026-08-13 | -14.34 |
| 2026-08-12 | -14.43 |
| 2026-08-11 | -14.18 |
| 2026-08-10 | -14.35 |
| 2026-08-07 | -16.63 |
| 2026-08-06 | -16.75 |
| 2026-08-05 | -16.83 |
| 2026-08-04 | -16.93 |
| 2026-08-03 | -16.93 |
| 2026-07-31 | -16.71 |
| 2026-07-30 | -16.72 |
| 2026-07-29 | -16.67 |
| 2026-07-28 | -16.56 |
| 2026-07-27 | -16.16 |
| 2026-07-24 | -16.11 |
| 2026-07-23 | -16.16 |
| 2026-07-22 | -16.29 |
| 2026-07-21 | -16.43 |
| 2026-07-20 | -16.48 |
| 2026-07-17 | -16.33 |